SGEN - Seagen - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

35.27B

Cash

1.49B

Avg Qtr Burn

-121.6M

Short % of Float

4.56%

Insider Ownership

0.91%

Institutional Own.

91.80%

Qtr Updated

03/31/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
TUKYSA (Tucatinib) Details Solid tumor/s, Colorectal cancer , Cancer, Metastatic colorectal cancer	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
PADCEV® Details Urothelial carcinoma	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TIVDAK (tisotumab vedotin-tftv) Details Cervical cancer	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ADCETRIS® (Brentuximab Vedotin) Details Hodgkin Lymphoma	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.